Biofarm Sp. z o. o. (Ltd.) is one of the leading Polish pharmaceutical manufacturers. The company was established in 1988. In 2001 Biofarm was one of the first Polish companies granted with the GMP certificate confirming their compliance with the highest quality standards for pharmaceutical production. This, together with constant development of their facility with state-of-the-art technology makes them a reliable partner.
With a global turnover of 110 million USD in 2013, Biofarm was ranked 19th among over 500 pharmaceutical companies from all over the world in the Polish market, and 3rd pharmaceutical manufacturer with solely Polish capital, which makes them a serious player in the domestic field. Their company’s competitive advantage is built mainly on a highly qualified staff and an excellent product portfolio, which currently includes over 80 medicinal products and numerous dietary supplements in the fields of cardiology, neurology, oncology, psychiatry, gastrology and general practice. Biofarm exports its production to over 10 countries all over the world.
Biofarm Sp. z o. o.
Tel. +48 61 665 16 29
13 Wałbrzyska St.
60-198 Poznań, Poland
e-mail: biofarm@biofarm.pl
“Average pharmaceutical company expenditures on R&D are in the range of 13 to 15 percent of revenues: much higher than the global average, and much higher than other Polish industrial…
Sabina Sampławska, director, head of life sciences at KPMG Poland, discusses the challenge of pricing pressures and how their innovative services help companies manage this trend, as well as the…
Michael Kern, director general of the German Chamber of Commerce in Poland, discusses the evolving economic and business landscape in Poland and the overall impact of German companies. Furthermore, he…
Adam Czerw, country manager of LEO Pharma Poland, discusses the impressive growth of the affiliate, especially since the global 2016 purchase of Astellas’ dermatology portfolio, as well as the encouraging…
Michał Pietraszek, general manager of Apotex Poland, the leading Canadian generics powerhouse, discusses the affiliate’s strategic move into the OTC and food supplement business and the company’s niche-market approach to…
Michael Dembinski, chief advisor of the British Polish Chamber of Commerce, discusses the important role of the chamber in driving forward Polish clinical trials and the challenges in unlocking Poland’s…
Mirosław Wysocki, national consultant in the area of Public Health, professor at the National Institute of Public Health (NIH), the research institute responsible inter alia for health promotion and disease…
Monika Constant, director general of the French-Polish Chamber of Commerce in Poland (CCIFP), discusses the evolution of the two nations’ bilateral business relationship, the benefits of conducting business in Poland,…
Beata Ambroziewicz, board member of the Polish cancer patient coalition, an umbrella organization that encompasses 41 Polish cancer organizations, discusses the challenges and possible solutions in regard to hospital care…
Bogna Cichowska-Duma, general director of the Employers’ Association of Innovative Pharmaceutical Companies (INFARMA), the voice of 28 leading innovative companies in Poland, discusses the challenges and opportunities for doing research…
Marcin Czech, deputy minister and undersecretary of state at the Polish Ministry of Health, provides an in-depth perspective on Poland’s drug policy framework and the new medicines policy that aims…
Mirosław Zieliński, president of the Polish National Forum for the Therapy of rare diseases (ORPHAN), the representative voice for 35 Polish rare disease associations, discusses the implications of the introduction…
Wojciech Kuta, editor-in-chief of Rynek Zdrowia, a leading Polish healthcare publication, discusses the interacting dynamics of the obstacles facing Polish healthcare, as the country aims to increase healthcare spending to…
See our Cookie Privacy Policy Here
